Search

Your search keyword '"Russo, Francesca"' showing total 1,510 results
Start Over Author "Russo, Francesca"
1,510 results on '"Russo, Francesca"'

5. 68Ga-Pentixafor

Author

Russo, Francesca, Menichini, Massimo, Ricci, Maria, Travascio, Laura, Dadgar, Habibollah, Arabi, Hossein, Norouzbeigi, Nasim, De Feo, Maria Silvia, Zaidi, Habib, Albalooshi, Batool, Cimini, Andrea, Calabria, Ferdinando, editor, and Schillaci, Orazio, editor

Published
2024
Full Text
View/download PDF

6. Single-cell guided prenatal derivation of primary fetal epithelial organoids from human amniotic and tracheal fluids

Author

Gerli, Mattia Francesco Maria, Calà, Giuseppe, Beesley, Max Arran, Sina, Beatrice, Tullie, Lucinda, Sun, Kylin Yunyan, Panariello, Francesco, Michielin, Federica, Davidson, Joseph R., Russo, Francesca Maria, Jones, Brendan C., Lee, Dani Do Hyang, Savvidis, Savvas, Xenakis, Theodoros, Simcock, Ian C., Straatman-Iwanowska, Anna A., Hirst, Robert A., David, Anna L., O’Callaghan, Christopher, Olivo, Alessandro, Eaton, Simon, Loukogeorgakis, Stavros P., Cacchiarelli, Davide, Deprest, Jan, Li, Vivian S. W., Giobbe, Giovanni Giuseppe, and De Coppi, Paolo

Published
2024
Full Text
View/download PDF

8. Tracheomalacia and tracheomegaly in infants and children with congenital diaphragmatic hernia managed with and without fetoscopic endoluminal tracheal occlusion (FETO): a multicentre, retrospective cohort study

Author

Basurto, David, Watananirun, Kanokwaroon, Cordier, Anne-Gael, Otaño, Juan, Carriere, Diane, Scuglia, Marianna, de Luna Freire Vargas, Anna Moraes, Prat, Jordi, Russo, Francesca Maria, Debeer, Anne, Peralta, Cleisson Fábio Andrioli, De Coppi, Paolo, Gratacós, Eduard, Benachi, Alexandra, and Deprest, Jan

Published
2024
Full Text
View/download PDF

15. Adverse events following Measles-Mumps-Rubella and varicella immunization: A safety profile analysis and comparison of different vaccination schedules based on the Italian Pharmacovigilance Network in the Veneto Region

Author

Soriolo, Nicola, Benoni, Roberto, Dalla Valle, Diana, Zunino, Francesco, Olivieri, Adele, Campagna, Irene, Tardivo, Stefano, Augusta Gonella, Laura, Russo, Francesca, Tonon, Michele, Da Re, Filippo, Moretti, Ugo, Zanoni, Giovanna, and Moretti, Francesca

Published
2024
Full Text
View/download PDF

16. Waste Aggregates in Asphalt Mixtures

Author

Pasquini, Emiliano, Moreno-Navarro, Fernando, Cannone Falchetto, Augusto, Pasetto, Marco, Giacomello, Giovanni, Tauste-Martinez, Raul, Wang, Di, Vaillancourt, Michel, Carter, Alan, Lachance-Tremblay, Éric, Viscione, Nunzio, Russo, Francesca, Skaf, Marta, Orešković, Marko, Freire, Ana Cristina, Hernando, David, Mikhailenko, Peter, Poulikakos, Lily D., Cannone Falchetto, Augusto, editor, Poulikakos, Lily, editor, Pasquini, Emiliano, editor, and Wang, Di, editor

Published
2023
Full Text
View/download PDF

17. Determinants of PFOA Serum Half-Life after End of Exposure: A Longitudinal Study on Highly Exposed Subjects in the Veneto Region

Author

Batzella, Erich, Rosato, Isabella, Pitter, Gisella, Re, Filippo Da, Russo, Francesca, Canova, Cristina, and Fletcher, Tony

Subjects
Half-Lives (Poetry collection) -- Research, Ammonium perfluorooctanoate -- Analysis -- Research, Drinking water -- Analysis -- Research, Water, Underground -- Research -- Analysis, Environmental issues, Health
Abstract

Background: Perfluoroalkyl substances (PFAS) are widely used, ubiquitous, and highly persistent man-made chemicals. Groundwater of a vast area of the Veneto Region (northeastern Italy) was found to be contaminated by PFAS from a manufacturing plant active since the late 1960s. As a result, residents were overexposed to PFAS through drinking water until 2013, mainly to perfluorooctanoic acid (PFOA). OBJECTIVES: The aim of the present study was to estimate the rates of decline in serum PFOA and their corresponding serum half-lives, while characterizing their determinants. Methods: We investigated 5,860 subjects more than 14 years of age who enrolled in the second surveillance round of the regional health surveillance program. Two blood samples were collected between 2017 and 2022 (average time between measurements: 4 years). Serum PFOA excretion rates and half-lives were estimated based on linear mixed effect models, modeling subject-specific serum PFOA concentrations over time and correcting for background concentrations. For modeling determinants of half-life [age, sex, body mass index (BMI), smoking- habit, alcohol consumption, and estimated glomerular filtration rate (eGFR)], we added interaction terms between each covariate and the elapsed time between measurements. Perfluorooctanesulfonate (PFOS) and perfluorohexanesulfonic acid (PFHxS) apparent half-lives were also estimated. A separate analysis was conducted in children (n = 480). All analyses were stratified by sex. Results: Median initial serum concentrations of PFOA was 49 ng/mL (range: 0.5- 1,090), with a median reduction of 62.45%. The mean estimated PFOA half-life was 2.36 years [95% confidence interval (CI): 2.33, 2.40], shorter in women (2.04; 95% CI: 2.00, 2.08) compared to men (2.83; 95% CI: 2.78, 2.89). Half-lives varied when stratified by some contributing factors, with faster excretion rates in nonsmokers and nonalcohol drinkers (especially in males). Conclusions: This study, to our knowledge the largest on PFOA half-life, provides precise estimates in young adults whose exposure via drinking water has largely ceased. For other PFAS, longer half-lives than reported in other studies can be explained by some ongoing exposure to PFAS via other routes. https://doi.org/10.1289/EHP13152, Introduction Perfluoroalkyl substances (PFAS) are a group of widely used, ubiquitous, and highly persistent man-made chemicals. (1) Despite the progressive phasing out of several long-chain PFAS from industrial processes, significant [...]

Published
2024
Full Text
View/download PDF

24. List of contributors

Author

Ademollo, Nicoletta, primary, Allegrini, Ivo, additional, Apollaro, Carmine, additional, Avci, A.H., additional, Bahamonde Soria, Raúl, additional, Cairns, Warren R.L., additional, Castro-Muñoz, Roberto, additional, Cavoura, Olga, additional, Di Gennaro, Gianfranco, additional, Figoli, Alberto, additional, Fuoco, Ilaria, additional, Galiano, Francesco, additional, Ianniello, Antonietta, additional, Iulianelli, Adolfo, additional, Li, Tianling, additional, Licata, Francesca, additional, Luis, Patricia, additional, Malankowska, M., additional, Manisco, Matteo, additional, Mondal, S., additional, Nobile, Carmelo G.A., additional, Papadopoli, Rosa, additional, Patrolecco, Luisa, additional, Pizzini, Sarah, additional, Polesello, Stefano, additional, Procopio, Antonio, additional, Rauseo, Jasmin, additional, Russo, Francesca, additional, Santoro, S., additional, Spataro, Francesca, additional, Syed, U.T., additional, Upadhyaya, L., additional, Valentini, Federica, additional, Vardè, Massimiliano, additional, Vespasiano, Giovanni, additional, Wang, Zhengguo, additional, Xing, Chao, additional, Zhang, Shanqing, additional, and Zhou, Ming, additional

Published
2023
Full Text
View/download PDF

25. List of contributors

Author

Abdellah, Mohamed, primary, Ahmad, Siti Nur Afifi Binti, additional, Akkurt, Gulden Gokcen, additional, Akther, Nawshad, additional, Al-Mutwalli, Sama A., additional, Al-Othman, Amani, additional, Altıok, Esra, additional, Arafat, Hassan A., additional, Baba, Alper, additional, Baig, Muhammad Irshad, additional, Cassano, Alfredo, additional, Cavalcante, Joyce, additional, Choo, Youngwoo, additional, Cihanoğlu, Aydın, additional, Conidi, Carmela, additional, de Vos, Wiebe M., additional, Donato, Laura, additional, Drioli, Enrico, additional, Dumée, Ludovic F., additional, Eti, Mine, additional, Figoli, Alberto, additional, Frappa, Mirko, additional, Galiano, Francesco, additional, Goh, Pei Sean, additional, Güler, Enver, additional, Gural, H. Berru, additional, Han, Dong-Suk, additional, Hu, Jiahui, additional, Ismail, Ahmad Fauzi, additional, Jaafar, Juhana, additional, Jarma, Yakubu A., additional, Kabay, Nalan, additional, Kaczmarczyk, Michał, additional, Kasztelewicz, Aleksandra, additional, Kaya, Tuğçe Zeynep, additional, Kharraz, Jehad A., additional, Koseoglu-Imer, Derya Y., additional, Kumari, Priyanka, additional, Lee, Adam F., additional, Liu, Yongjie, additional, Macedonio, Francesca, additional, Mamah, Stanley Chinedu, additional, Mavukkandy, Musthafa O., additional, Merenda, Andrea, additional, Mizan, Md Mizanul Haque, additional, Moghadasin, Mohammad Hosein, additional, Mohammadi, Toraj, additional, Mukti, Mentari, additional, Naidu, Gayathri, additional, Omi, Farah Rahman, additional, Othman, Mohd Hafiz Dzarfan, additional, Pathak, Nirenkumar, additional, Pishbin, Roshanak, additional, Rahman, Mukhlis A., additional, Russo, Francesca, additional, Sadrzadeh, Mohtada, additional, Samrajyam, Sathya Aamuktha, additional, Sanaeepur, Hamidreza, additional, Seyedpour, Fatemeh, additional, Sheikh, Jawwad Imran, additional, Shirazi, Mohammad Mahdi A., additional, Shon, Hokyong, additional, Sreedhar, Nurshaun, additional, Sultana, Hamadia, additional, Szekely, Gyorgy, additional, Taher, Mustafa N., additional, Tawalbeh, Muhammad, additional, Tofighy, Maryam Ahmadzadeh, additional, Tomaszewska, Barbara, additional, Vigile, Maria Francesca, additional, Wilson, Karen, additional, Yaacoubi, Hind, additional, and Yu, Hanwei, additional

Published
2023
Full Text
View/download PDF

26. Membranes for air cleaning

Author

Russo, Francesca, primary, Manisco, Matteo, additional, Iulianelli, Adolfo, additional, Castro-Muñoz, Roberto, additional, Galiano, Francesco, additional, and Figoli, Alberto, additional

Published
2023
Full Text
View/download PDF

27. Wastewater surveillance of SARS-CoV-2 variants in October–November 2022 in Italy: detection of XBB.1, BA.2.75 and rapid spread of the BQ.1 lineage

Author

Palma, Achille, Calabria, Adelaide, Carnevali, Agnese, Nehludoff, Albano, Stenico, Alberta, Izzotti, Alberto, Barca, Alessandra, Tosco, Alessandra, Porta, Amalia, Lombardi, Annalisa, Voli, Antonia, Franzetti, Andrea, Ciccaglione, Angela, Costa, Angela, D’Argenzio, Angelo, Romano, Angelo, Pariani, Anna, Carducci, Annalaura, Grucci, Annalisa, Prast, Anna-Maria, Agodi, Antonella, Cersini, Antonella, Giorgi, Antonella, Bertasi, Barbara, Griglio, Bartolomeo, Ancona, Carla, Maida, Carmelo Massimo, Montanaro, Carmen, Filizzolo, Chiara, Ottaviano, Claudio, Cocuzza, Clementina, Pignata, Cristina, Nasci, Daniele, Cereda, Danilo, Oliva, Desdemona, Giorgi, Doriana Antonella, Malacaria, Edoardo, Grasselli, Elena, Nicosia, Elena, Carraro, Elisabetta, Ammoni, Emanuela, Grange, Eric, Federici, Ermanno, Filippetti, Fabio, Tramuto, Fabio, Guarneri, Flavia, Serio, Flavia, Damasco, Florida, Palumbo, Franca, Apollonio, Francesca, Cutrupi, Francesca, Gucciardi, Francesca, Pennino, Francesca, Russo, Francesca, Triggiano, Francesco, Rigoli, Franco, Pietrella, Gabriele, Trani, Gabriella, Rossolini, Gian Maria, Bulotta, Giorgia, Fusco, Giovanna, La Vecchia, Giovanna, Alborali, Giovanni, Giammanco, Giovanni, Santoro, Giovanni, Pitter, Gisella, Purpari, Giuseppa, Aprea, Giuseppe, Di Vittorio, Giuseppe, Folino, Giuseppe, Lauria, Giuseppe, Federigi, Ileana, Amoruso, Irene, Ferrante, Irene, Tomesani, Irene, De Lellis, Laura, Pellegrinelli, Laura, Demetz, Lea, Gentili, Lisa, Richiardi, Lisa, Zago, Lorella, Masieri, Lorena, Decastelli, Lucia, Bolognini, Luigi, Cossentino, Luigi, Bianchi, Manila, Verani, Marco, Zampini, Marco, Ferrante, Margherita, Cadonna, Maria, Montagna, Maria Teresa, Scicluna, Maria Teresa, Arizzi, Mariaconcetta, Mariuz, Marika, Palermo, Mario, Bellisomi, Marta, Paniccià, Marta, Barchitta, Martina, Ramazzotti, Matteo, Postinghel, Mattia, Viscardi, Maurizio, Ruffier, Mauro, Petricciuolo, Maya, La Bianca, Michele, Colitti, Michele, Monfrinotti, Monica, Fontani, Nadia, Formenti, Nicoletta, Mongelli, Onofrio, De Giglio, Osvalda, Angelini, Paola, Foladori, Paola, Torlontano, Paolo, Calà, Piergiuseppe, Cifarelli, Rosa Anna, Binda, Sandro, Briscolini, Sara, Castiglioni, Sara, Bonetta, Silvia, Magi, Silvia, Scattolini, Silvia, Schiarea, Silvia, De Grazia, Simona, Rosatto, Stefano, Baldovin, Tatjana, Primache, Valeria, Groppi, Vanessa, Acciari, Vicdalia Aniela, Mazzucco, Walter, La Rosa, G., Brandtner, D., Bonanno Ferraro, G., Veneri, C., Mancini, P., Iaconelli, M., Lucentini, L., Del Giudice, C., Orlandi, L., and Suffredini, E.

Published
2023
Full Text
View/download PDF

29. Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): overall survival and updated results of a randomised, double-blind, phase 3 trial.

Author

Petrylak, Daniel, de Wit, Ronald, Chi, Kim, Drakaki, Alexandra, Sternberg, Cora, Nishiyama, Hiroyuki, Castellano, Daniel, Hussain, Syed, Fléchon, Aude, Bamias, Aristotelis, Yu, Evan, van der Heijden, Michiel, Matsubara, Nobuaki, Alekseev, Boris, Necchi, Andrea, Géczi, Lajos, Ou, Yen-Chuan, Coskun, Hasan, Su, Wen-Pin, Bedke, Jens, Gakis, Georgios, Percent, Ivor, Lee, Jae-Lyun, Tucci, Marcello, Semenov, Andrey, Laestadius, Fredrik, Peer, Avivit, Tortora, Giampaolo, Safina, Sufia, Garcia Del Muro, Xavier, Rodriguez-Vida, Alejo, Cicin, Irfan, Harputluoglu, Hakan, Tagawa, Scott, Vaishampayan, Ulka, Aragon-Ching, Jeanny, Hamid, Oday, Liepa, Astra, Wijayawardana, Sameera, Russo, Francesca, Walgren, Richard, Zimmermann, Annamaria, Hozak, Rebecca, Bell-McGuinn, Katherine, and Powles, Thomas

Subjects
Aged, Antibodies, Monoclonal, Humanized, Antineoplastic Combined Chemotherapy Protocols, Carcinoma, Transitional Cell, Docetaxel, Double-Blind Method, Female, Follow-Up Studies, Humans, Male, Middle Aged, Neoplasm Invasiveness, Neoplasm Metastasis, Platinum, Prognosis, Salvage Therapy, Survival Rate, Urologic Neoplasms, Ramucirumab
Abstract

BACKGROUND: Ramucirumab-an IgG1 vascular endothelial growth factor receptor 2 antagonist-plus docetaxel was previously reported to improve progression-free survival in platinum-refractory, advanced urothelial carcinoma. Here, we report the secondary endpoint of overall survival results for the RANGE trial. METHODS: We did a randomised, double-blind, phase 3 trial in patients with advanced or metastatic urothelial carcinoma who progressed during or after platinum-based chemotherapy. Patients were enrolled from 124 investigative sites (hospitals, clinics, and academic centres) in 23 countries. Previous treatment with one immune checkpoint inhibitor was permitted. Patients were randomly assigned (1:1) using an interactive web response system to receive intravenous ramucirumab 10 mg/kg or placebo 10 mg/kg volume equivalent followed by intravenous docetaxel 75 mg/m2 (60 mg/m2 in Korea, Taiwan, and Japan) on day 1 of a 21-day cycle. Treatment continued until disease progression, unacceptable toxicity, or other discontinuation criteria were met. Randomisation was stratified by geographical region, Eastern Cooperative Oncology Group performance status at baseline, and visceral metastasis. Progression-free survival (the primary endpoint) and overall survival (a key secondary endpoint) were assessed in the intention-to-treat population. The study is registered with ClinicalTrials.gov, NCT02426125; patient enrolment is complete and the last patient on treatment is being followed up for safety issues. FINDINGS: Between July 20, 2015, and April 4, 2017, 530 patients were randomly allocated to ramucirumab plus docetaxel (n=263) or placebo plus docetaxel (n=267) and comprised the intention-to-treat population. At database lock (March 21, 2018) for the final overall survival analysis, median follow-up was 7·4 months (IQR 3·5-13·9). In our sensitivity analysis of investigator-assessed progression-free survival at the overall survival database lock, median progression-free survival remained significantly improved with ramucirumab compared with placebo (4·1 months [95% CI 3·3-4·8] vs 2·8 months [2·6-2·9]; HR 0·696 [95% CI 0·573-0·845]; p=0·0002). Median overall survival was 9·4 months (95% CI 7·9-11·4) in the ramucirumab group versus 7·9 months (7·0-9·3) in the placebo group (stratified HR 0·887 [95% CI 0·724-1·086]; p=0·25). Grade 3 or worse treatment-related treatment-emergent adverse events in 5% or more of patients and with an incidence more than 2% higher with ramucirumab than with placebo were febrile neutropenia (24 [9%] of 258 patients in the ramucirumab group vs 16 [6%] of 265 patients in the placebo group) and neutropenia (17 [7%] of 258 vs six [2%] of 265). Serious adverse events were similar between groups (112 [43%] of 258 patients in the ramucirumab group vs 107 [40%] of 265 patients in the placebo group). Adverse events related to study treatment and leading to death occurred in eight (3%) patients in the ramucirumab group versus five (2%) patients in the placebo group. INTERPRETATION: Additional follow-up supports that ramucirumab plus docetaxel significantly improves progression-free survival, without a significant improvement in overall survival, for patients with platinum-refractory advanced urothelial carcinoma. Clinically meaningful benefit might be restricted in an unselected population. FUNDING: Eli Lilly and Company.

Published
2020

30. Stone Paved Road Digital Reproduction: A Workflow

Author

Intignano, Mattia, Biancardo, Salvatore Antonio, Oreto, Cristina, Viscione, Nunzio, Veropalumbo, Rosa, Russo, Francesca, Abbondati, Francesco, Dell’Acqua, Gianluca, Kacprzyk, Janusz, Series Editor, Prentkovskis, Olegas, editor, Yatskiv (Jackiva), Irina, editor, Skačkauskas, Paulius, editor, Junevičius, Raimundas, editor, and Maruschak, Pavlo, editor

Published
2022
Full Text
View/download PDF

31. An Interlaboratory Test Program on the Extensive Use of Waste Aggregates in Asphalt Mixtures: Preliminary Steps

Author

Pasetto, Marco, Pasquini, Emiliano, Giacomello, Giovanni, Moreno-Navarro, Fernando, Tauste-Martinez, Raul, Cannone Falchetto, Augusto, Vaillancourt, Michel, Carter, Alan, Viscione, Nunzio, Russo, Francesca, Skaf, Marta, Orešković, Marko, Freire, Ana Cristina, Mikhailenko, Peter, Poulikakos, Lily, Di Benedetto, Hervé, editor, Baaj, Hassan, editor, Chailleux, Emmanuel, editor, Tebaldi, Gabriele, editor, Sauzéat, Cédric, editor, and Mangiafico, Salvatore, editor

Published
2022
Full Text
View/download PDF

35. Self‐reported respiratory and gastrointestinal outcomes in children with isolated congenital diaphragmatic hernia: A prospective multicentre study

Author

Eastwood, Mary Patrice, primary, Van der Veeken, Lennart, additional, Joyeux, Luc, additional, Salazar, Laura, additional, Otano, Juan, additional, d'Souza, Rashmi, additional, Sidler, Martin, additional, Russo, Francesca Maria, additional, Prat, Jordi, additional, de Coppi, Paolo, additional, Gratacós, Eduard, additional, and Deprest, Jan, additional

Published
2024
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results